Scope of report
- The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis III.
- The report assesses Mucopolysaccharidosis III pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Mucopolysaccharidosis III pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Mucopolysaccharidosis III ranging from discovery to pre-registration and undisclosed stages.
Saneron CCEL Therapeutics, Shire Pharmaceuticals Group, Zacharon Pharmaceuticals, Synageva BioPharma, Amsterdam Molecular Therapeutics, LYSOGENE, Shire, BioMarin Pharmaceutical, Genea Biocells, Novogen, ArmaGen Technologies, DORPHAN S.A., Orchard Therapeutics, BioStrategies LC, Axcentua Pharmaceuticals
Recombinant human alpha-1 antitrypsin, VX 563, CTX 100, AGTC 0106
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800